Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar

Rare Tumors

Authors: Areeba Fareed, Nimrah Inam, Fatima Faraz

DOI: https://doi.org/10.1177/20363613231183785

Publish Year: 2023